IF a small-molecule positive allosteric modulator (PAM-GLO1), identified via fragment-based drug design (FBDD) targeting the Tyr136-proximal homodimer interface pocket of GLO1 (computationally identified on AlphaFold model AF-Q04760-F1, excluding zinc-binding active-site residues His127, Glu173, Gln34, Glu100 and the orthosteric hydrophobic inhibitor pocket residues F62, L69, F71, I88, L92, V149, K150, F162, W170), is administered systemically (i.p. or oral gavage, dose TBD by Phase 1 SAR) to aged (20–24 month), male and female C57BL/6J mice exhibiting established hyperglycemia-associated tissue methylglyoxal (MG) accumulation and advanced glycation end-product (AGE) burden,

THEN GLO1 homodimer catalytic activity will increase ≥2-fold over vehicle in liver and kidney homogenates, tissue-free MG will decrease ≥40%, and quantifiable pre-existing AGE adduct burden (measured by fluorescent AGE ELISA, LC-MS/MS MG-derived hydroimidazolone (MG-H1) adducts on tissue protein digests, and carboxymethyl-lysine (CML) immunohistochemistry) will be significantly reduced within 8 weeks,

BECAUSE the following causal chain operates:

1. Tyr136 phosphorylation is the principal positive regulatory post-translational modification of GLO1: phospho-Tyr136 promotes enzymatic activity across multiple cell types and mouse models, demonstrated via kinase overexpression and phosphomimetic Y136E mutation studies (GLO1 activity is promoted by phosphorylation on Tyrosine 136 via multiple kinases)[https://pubmed.ncbi.nlm.nih.gov/34838714/].
2. In hyperglycemia (pathological glucose concentrations above physiological 5 mM), Tyr136 phosphorylation decreases in both cell culture and mouse models of hyperglycemia, reducing GLO1 activity and causing MG to accumulate (Glo1 Y136 phosphorylation responds in a bimodal fashion to glucose levels, decreasing at higher glucose concentrations)[https://pubmed.ncbi.nlm.nih.gov/34838714/]. In aging tissues, chronic low-grade hyperglycemia and kinase dysregulation recapitulate this phosphorylation-deficient state.
3. Tyr136 sits at or near the homodimer interface of GLO1 (established from PDB structures 1QIN and 1FRO, where the active site is formed across the two subunits via His127, Glu173, Gln34, Glu100). Phosphorylation of Tyr136 likely stabilizes a specific dimer contact geometry that favors the catalytically active conformation. A small molecule binding to the interface pocket adjacent to Tyr136 could mimic the electrostatic and steric effects of the phosphate group, constitutively stabilizing this active dimer geometry without requiring upstream kinase activity. [SPECULATIVE — dimer interface contact geometry at Tyr136 must be confirmed by computational pocket detection on AF-Q04760-F1/1QIN.]
4. Stabilization of the catalytically competent dimer by PAM-GLO1 would increase the effective rate of MG-glutathione hemimercaptal isomerization to S-lactoylglutathione, accelerating MG clearance even in the phosphorylation-deficient aged/hypergl...

SENS category: GlycoSENS